Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Missing Piece study guiding new strategies to prevent rheumatic fever

A Kimberley study seeking to better understand Strep A in remote settings is helping to guide new approaches to prevent acute rheumatic fever (ARF) – an auto-immune response that typically begins with a sore throat and causes high fever, tiredness and swollen joints.

Validity of using a semi-automated screening tool in a systematic review assessing non-specific effects of respiratory vaccines

The abstract screening process of systematic reviews can take thousands of hours by two researchers. We aim to determine the reliability and validity of Research Screener, a semi-automated abstract screening tool within a systematic review on non-specific and broader effects of respiratory vaccines on acute lower respiratory infection hospitalisations and antimicrobial prescribing patterns in young children.

More than a good night's sleep: why a preterm baby's body clock may unlock the secret to life-long health

A simple set of eye masks and ear plugs – an inexpensive solution explored in a successful pilot study by The Kids Research Institute Australia, together with the Child and Adolescent Health Service – could hold the key to better outcomes for our tiniest bubs. Now, a nationwide clinical trial is testing the idea

Database a crucial tool helping to fill the CDKL5 information void

The Kids Research Institute Australia disability researcher, Associate Professor Helen Leonard, played an important role in the identification of the differences that define CDD, thanks to her extensive experience researching Rett syndrome and running an Australian online database tracking Rett cases.

Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients

The success of cancer immunotherapies has highlighted the importance of monitoring the anti-tumour T cell response. Patients with mesothelioma frequently present with a malignant pleural effusion (MPE) that is commonly drained regularly to alleviate symptoms. As MPE contains tumour cells, T cells and cytokines, it provides a unique opportunity to sample immune events at the tumour site.

Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery

Subcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed.

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines

Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity. 

Mapping the prevalence of soil-transmitted helminth infections in the Western Pacific Region: a spatial modelling study

Soil-Transmitted Helminth (STH) infections are a significant health issue in the Western Pacific Region (WPR). This study aims to produce high-resolution spatial prediction STH prevalence maps for the WPR.

Working with the community

Community involvement plays an integral role in guiding our research - find out how.

Parents' COVID-19 vaccine intentions for children under 5 years: Brief reflections from a qualitative study

Australian authorities made COVID-19 vaccines available for children aged under 5 years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years.